22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › AXSOME THERAPEUTICS INC. › 2024-2025

AXSOME THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 346Asset managers, any item
  • 1,519Fund votes
  • June 6, 2025Meeting date

Results at a glance

Meeting of June 6, 2025: 4 items on AXSOME THERAPEUTICS INC.’s Form 8-K, filed June 9, 2025: 1 elected · 3 approved.

Dissent

Significant dissent: 1 director (22.8% against); 1 equity or compensation plan (25.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AXSOME THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AXSOME THERAPEUTICS INC.

These tallies are AXSOME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AXSOME THERAPEUTICS INC. — official shareholder meeting results, meeting held June 6, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Roger A. Jeffs, Ph.D. 27,307,185---- 8,050,9596,010,496 77%Elected—
2. Approval of the Company's 2025 Long-Term Incentive Plan 26,403,6258,893,06861,451 --6,010,496 75%Approved—
3. Ratification of Appointment of Deloitte & Touche LLP 40,849,740225,677293,223 --0 99.5%Approved—
4. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers 34,776,343528,19953,602 --6,010,496 99%Approved—

Source: AXSOME THERAPEUTICS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the AXSOME THERAPEUTICS INC. 2024-2025 meeting

346 asset managers disclosed a vote on at least one AXSOME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Roger A. Jeffs, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 27,307,185WITHHELD: 8,050,959
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: Election of Director: Roger Jeffs, Ph.D.

AXSOME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roger A. Jeffs, Ph.D.”): 27,307,185 for, 8,050,959 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following director to serve as a Class I director until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 8,265,347 for, 3,496,726 withheld, 0 abstained.

FORWITHHOLD
FOR: 8,265,347ABSTAIN: 0WITHHOLD: 3,496,726
Largest asset managers voting on “Election of Director: Roger Jeffs, Ph.D.” at AXSOME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,805,5970 0311For
Fidelity1,568,2230 00For
BlackRock992,3530 00For
MUTUAL FUND SERIES TRUST742,0650 00For
Delaware/Macquarie00 0705,954Withhold
Invesco00 0689,907Withhold
TIAA00 0381,193Withhold
Charles Schwab340,8600 00For
Putnam200,6500 00For
T. Rowe Price00 0199,412Withhold
Loomis Sayles00 0162,529Withhold
Waddell & Reed00 0139,244Withhold
Principal1290 0137,700Withhold
Equitable91,6530 045,190Mixed
Hartford95,9920 00For
Jackson National60,2900 028,911Mixed
Aberdeen00 081,916Withhold
Lincoln Financial27,1000 044,031Mixed
DWS00 065,679Withhold
First Trust00 064,278Withhold
QUANTITATIVE MASTER SERIES LLC62,7470 00For
VanEck ETF Trust00 061,282Withhold
Voya00 056,802Withhold
CARILLON SERIES TRUST00 055,770Withhold
Nuveen00 048,397Withhold

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Approval of the Company's 2025 Long-Term Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

75% Approved · of votes cast

FOR 75%AGAINST
FOR: 26,403,625AGAINST: 8,893,068
Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: To approve the Company's 2025 Long-Term Incentive Plan.

AXSOME THERAPEUTICS INC.’s own tally for this item (“2. Approval of the Company's 2025 Long-Term Incentive Plan”): 26,403,625 for, 8,893,068 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve the 2025 Long-Term Incentive Plan.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 8,316,783 for, 3,394,090 against, 25,750 abstained.

FORAGAINST
FOR: 8,316,783AGAINST: 3,394,090ABSTAIN: 25,750
Largest asset managers voting on “To approve the Company's 2025 Long-Term Incentive Plan.” at AXSOME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,805,9080 00For
Fidelity1,568,2230 00For
BlackRock992,3530 00For
MUTUAL FUND SERIES TRUST742,0650 00For
Delaware/Macquarie0705,954 00Against
Invesco0689,907 00Against
TIAA0381,193 00Against
Charles Schwab340,8600 00For
Putnam0200,650 00Against
T. Rowe Price187,77411,638 00Mixed
Loomis Sayles162,5290 00For
Waddell & Reed0139,244 00Against
Principal129137,700 00Against
Equitable91,65345,190 00Mixed
Hartford95,9920 00For
Jackson National089,201 00Against
Aberdeen081,916 00Against
Lincoln Financial071,131 00Against
DWS065,679 00Against
First Trust064,278 00Against
QUANTITATIVE MASTER SERIES LLC62,7470 00For
VanEck ETF Trust61,2820 00For
Voya056,802 00Against
CARILLON SERIES TRUST055,770 00Against
Nuveen048,397 00Against

Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).

Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 34,776,343AGAINST: 528,199

Prior year: 97.4% for (June 7, 2024 meeting) ▲ 1.1 pts

Details: description as filed, official tally, votes by 342 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.

AXSOME THERAPEUTICS INC.’s own tally for this item (“4. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 34,776,343 for, 528,199 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AXSOME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Section 14a Executive Compensation” (2 managers, 19 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 93 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at AXSOME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,805,597311 00For
Fidelity1,568,2230 00For
BlackRock992,3530 00For
MUTUAL FUND SERIES TRUST742,0650 00For
Delaware/Macquarie705,9540 00For
Invesco689,9070 00For
TIAA381,1930 00For
Charles Schwab340,8600 00For
Putnam200,6500 00For
T. Rowe Price199,4120 00For
Loomis Sayles162,5290 00For
Waddell & Reed139,2440 00For
Principal137,8290 00For
Equitable136,8430 00For
Hartford95,9920 00For
Jackson National89,2010 00For
Aberdeen81,9160 00For
Lincoln Financial71,1310 00For
DWS65,6790 00For
First Trust64,2780 00For
QUANTITATIVE MASTER SERIES LLC62,7470 00For
VanEck ETF Trust61,2820 00For
Voya56,8020 00For
CARILLON SERIES TRUST55,7700 00For
Nuveen48,3970 00For

Fund voting reports, all 93 managers: 11,756,450 for, 1,463 against, 3,867 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 274 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at AXSOME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP2,826,7080 00For
BVF INC/IL1,690,2210 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,032,7190 00For
BlackRock988,5200 00For
Fidelity948,5660 00For
GEODE CAPITAL MANAGEMENT, LLC941,6460 00For
Fairmount Funds Management LLC815,1760 00For
Invesco785,9820 00For
Wellington481,1230 00For
State Street451,4620 00For
Nuveen434,4800 00For
PFM Health Sciences, LP423,4400 00For
ORBIMED ADVISORS LLC399,2000 00For
Charles Schwab340,9220 00For
Man Group plc334,6900 00For
T. Rowe Price323,3200 00For
1832 Asset Management L.P.320,7000 00For
Deep Track Capital, LP300,0000 00For
PICTET ASSET MANAGEMENT SA297,4440 00For
Putnam285,4820 00For
Woodline Partners LP275,5210 00For
Loomis Sayles248,4810 00For
Northern Trust237,7620 00For
PNC BANK, NATIONAL ASSOCIATION200,37429 00For
PRINCIPAL GLOBAL INVESTORS197,5650 00For

Institutional-manager reports, all 274 managers: 18,430,043 for, 257,875 against, 10,899 abstained, 11 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Deloitte & Touche LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 40,849,740AGAINST: 225,677
Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.

AXSOME THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of Deloitte & Touche LLP”): 40,849,740 for, 225,677 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AXSOME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 556 for).

The 93 asset managers below reported 11,738,695 for, 18,973 against, 3,867 abstained.

FOR
FOR: 11,738,695AGAINST: 18,973ABSTAIN: 3,867
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting f” at AXSOME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard3,805,9080 00For
Fidelity1,568,2230 00For
BlackRock992,3530 00For
MUTUAL FUND SERIES TRUST742,0650 00For
Delaware/Macquarie705,9540 00For
Invesco689,9070 00For
TIAA381,1930 00For
Charles Schwab340,8600 00For
Putnam200,6500 00For
T. Rowe Price199,4120 00For
Loomis Sayles162,5290 00For
Waddell & Reed139,2440 00For
Principal137,8290 00For
Equitable136,8430 00For
Hartford95,9920 00For
Jackson National89,2010 00For
Aberdeen81,9160 00For
Lincoln Financial71,1310 00For
DWS65,6790 00For
First Trust64,2780 00For
QUANTITATIVE MASTER SERIES LLC62,7470 00For
VanEck ETF Trust61,2820 00For
Voya56,8020 00For
CARILLON SERIES TRUST55,7700 00For
Nuveen48,3970 00For

Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).

Largest AXSOME THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,216,759 shares outstanding at the time of that meeting.

Fund voting reports: top AXSOME THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 7.73%
2Fidelity 3.19%
3BlackRock 2.02%
4MUTUAL FUND SERIES TRUST 1.51%
5Delaware/Macquarie 1.43%
6Invesco 1.40%
7TIAA 0.77%
8Charles Schwab 0.69%
9Putnam 0.41%
10T. Rowe Price 0.41%
Institutional-manager reports: top AXSOME THERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 5.74%
2BVF INC/IL 3.43%
3MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 2.10%
4BlackRock 2.01%
5Fidelity 1.93%
6GEODE CAPITAL MANAGEMENT, LLC 1.91%
7Fairmount Funds Management LLC 1.66%
8Invesco 1.60%
9Wellington 0.98%
10State Street 0.92%

Reported AXSOME THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

AXSOME THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Herriot Tabuteau, M.D.9,357,727 19.01%Proxy statement (DEF 14A), proxy filed April 25, 2025
Antecip Capital LLC7,344,500 14.92%Proxy statement (DEF 14A), proxy filed April 25, 2025
Vanguard Group3,876,942 7.88%Form 13F, quarter ended March 31, 2025
BlackRock3,524,411 7.16%Form 13F, quarter ended March 31, 2025
RTW Investments, LP1,516,903 3.08%Schedule 13G, filed August 14, 2025
FMR (Fidelity)1,247,231 2.53%Form 13F, quarter ended March 31, 2025
Geode Capital934,853 1.90%Form 13F, quarter ended March 31, 2025
State Street906,020 1.84%Form 13F, quarter ended March 31, 2025
Invesco857,001 1.74%Form 13F, quarter ended March 31, 2025
Wellington Management703,279 1.43%Form 13F, quarter ended March 31, 2025

Percentages above are of 49,216,759 shares outstanding, as reported by AXSOME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At AXSOME THERAPEUTICS INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 346 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,519 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — AXSOME THERAPEUTICS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AXSOME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AXSOME THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

AXSOME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “AXSOME THERAPEUTICS (AXSM) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/axsome-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.